Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons

Therapeutic Drug Monitoring

Volumn 25, Issue 2, 2003, Pages 229-233

  Koks, Cees H W ^a   Huitema, Alwin D R ^a   Kroon, Eugene D M B ^b,c   Chuenyam, Theshinee ^b,c   Sparidans, Rolf W ^d   Lange, Joep M A ^b,c   Beijnen, Jos H ^a,d  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Hydroxyitraconazole; Itraconazole; NONMEM; Population pharmacokinetics

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; DRUG METABOLITE; HYDROXYITRACONAZOLE; ITRACONAZOLE; LAMIVUDINE; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THAILAND;

ADULT; ANTIFUNGAL AGENTS; BAYES THEOREM; BIOLOGICAL AVAILABILITY; CANDIDIASIS, ORAL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HUMANS; ITRACONAZOLE; MODELS, BIOLOGICAL; THAILAND; TIME FACTORS;

EID: 0037381863     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200304000-00014     Document Type: Article

References (13)

1. Haria M, Bryson HM, Goa KL. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs. 1996;51:585-520.
2. Poirer J-M, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet. 1998;35:461-473.
3. Prentice HG, Caillot D, Dupont B, et al. Oral and intravenous itraconazole for systemic fungal infections in neutropenic hematological patients: meeting report. Acta Haematol. 1999;101:56-62.
4. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin Infect Dis. 1997;24:235-247.
5. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs. 2001;61 Suppl 1:27-37.
6. Koks CHW, Sparidans RW, Lucassen G, et al. Selective highperformance liquid chromatographic assay for itraconazole in plasma from human immunodeficiency virus-infected patients. J Chromatogr B. 2002;767:103-110.
7. Beal SL, Sheiner LB. NONMEM User's Guides. San Francisco: NONMEM Project Group, University of California at San Francisco, 1998.
8. Johnsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic-pharmacodynamic model building aid for NONMEM. Comp Meth Prog Biomed. 1998;58:51-64.
9. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokin Biopharm. 1993;21:735-50.
10. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32 Suppl 1:67-87.
11. Moreno F, Hardin TC, Rinaldi M, et al. Itraconazole-didanosine excipient interaction [letter]. JAMA. 1993;269:1508.
12. May DB, Drew RH, Yedinak KC, et al. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy. 1994;14:509-513.
13. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism. Clin Pharmacokinet. 2000;38:111-180.